# RNDO-564 alone or with pembrolizumab

Source: https://onco.cc/trials/nct07218003/  
OnCo record `nct07218003` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This early study tests RNDO-564 alone or with pembrolizumab in selected advanced tumors. It examines dose, side effects and early treatment activity.

## Summary

This early study tests RNDO-564 alone or with pembrolizumab in selected advanced tumors. It examines dose, side effects and early treatment activity.

Interventional study registered as NCT07218003, sponsored by Rondo Therapeutics. Registry phase: 1. Registry enrollment is 149 participants (estimated). Registry status checked October 10, 2026: enrolling by invitation. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-10
- Also known as: A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
- Tags: ucsf-breast-coverage; interventional
- Registry id: NCT07218003
- Phase: 1
- Setting: Selected advanced solid tumors associated with Nectin-4
- Sponsor: Rondo Therapeutics

## Sources

- ClinicalTrials.gov NCT07218003: https://clinicaltrials.gov/study/NCT07218003
- UCSF study listing and local availability: https://clinicaltrials.ucsf.edu/trial/NCT07218003

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct07218003.json